Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

MLA

Gabriel N. Hortobagyi. “Ribociclib for the First-Line Treatment of Advanced Hormone Receptor-Positive Breast Cancer: A Review of Subgroup Analyses from the MONALEESA-2 Trial.” Breast Cancer Research, vol. 20, no. 1, Oct. 2018, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s13058-018-1050-7.

APA

Gabriel N. Hortobagyi. (2018). Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Research, 20(1), 1–11. https://doi.org/10.1186/s13058-018-1050-7

Chicago

Gabriel N. Hortobagyi. 2018. “Ribociclib for the First-Line Treatment of Advanced Hormone Receptor-Positive Breast Cancer: A Review of Subgroup Analyses from the MONALEESA-2 Trial.” Breast Cancer Research 20 (1): 1–11. doi:10.1186/s13058-018-1050-7.